According to GlobalData’s medical device pipeline database, ten Anti-Mullerian Hormone (AMH) Lab Tests devices are in various stages of development globally. GlobalData’s report provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, five are in active development, while the remaining five are in an inactive stage of development. All devices are in the early stages of development.
The levels of AMH, a hormone produced by the granulosa cells in ovarian follicles, are evaluated in a blood test and used to monitor ovarian reserve. AMH levels remain fairly constant during all stages of a woman’s menstrual cycle, meaning the test can be performed at any time. Results can be used to predict the successfulness of in vitro fertilization (IVF) and the onset of menopause, as well as to evaluate premature ovarian failure associated with decreased fertility. One unit refers to one AMH test.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
See Also:
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Anti-Mullerian Hormone (AMH) Lab Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Anti-Mullerian Hormone (AMH) Lab Tests devices. Overall, most of these Anti-Mullerian Hormone (AMH) Lab Tests pipeline devices are being developed by private entities.
Key players involved in the active development of Anti-Mullerian Hormone (AMH) Lab Tests include Siemens Healthcare Diagnostics, University of Otago, Aura Biotechnologies, Beckman Coulter, Northwestern University, Paramedical and Shahid Beheshti University.
For a complete picture of the developmental pipeline for Anti-Mullerian Hormone (AMH) Lab Tests devices, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
